Search for Clinical Trial Results

Sponsored By

Sezary Syndrome - 12 Studies Found

Status Study
Terminated Study Name: Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
Condition:
  • Sezary Syndrome
  • Pruritus

Date: 2012-06-19
Interventions:
  • Drug: Aprepitant Aprepitant wi
Completed Study Name: Immunization Against Tumor Cells in Sezary Syndrome
Condition:
  • Cutaneous T-cell Lymphoma
  • Sezary Syndrome

Date: 2004-12-17
Interventions: Biological: Autologous Dendritic Cell Vaccine
Completed Study Name: VircapSeq Virus Detection in Sézary Syndrome
Condition:
  • Lymphoma, T-Cell, Cutaneous
  • Sézary Syndrome

Date: 2016-07-15
Terminated Study Name: Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Condition: Lymphoma
Date: 1999-12-10
Interventions: Drug: temozolomide Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a to
Completed Study Name: Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Condition: Lymphoma
Date: 1999-11-01
Interventions: Drug: tretinoin
Terminated Study Name: Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Condition: Lymphoma
Date: 2000-06-02
Interventions: Biological: aldesleukin
Active, not recruiting Study Name: Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
Condition: Lymphoma
Date: 2003-04-07
Interventions: Biological: alemtuzumab Will be administered as a two-hour IV infusion with a target dose of 30 milligra
Not yet recruiting Study Name: Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome
Condition:
  • Recurrent Mycosis Fungoides and Sezary Syndrome
  • Refractory Myco
    Date: 2017-02-22
    Interventions:
    • Biological: Interferon Gamma-1b

Active, not recruiting Study Name: Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Condition: Lymphoma
Date: 2007-04-25
Interventions: Drug: lenalidomide 10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cy
Completed Study Name: Effect of Denileukin Diftitox on Immune System in CTCL Patients
Condition:
  • Cutaneous T-cell Lymphoma
  • Sezary Syndrome